Poulos S P, Hausman G J
Animal Physiology Research Unit, Richard B. Russell Agricultural Research Center, USDA-ARS, Athens, GA 30605-2720, USA.
J Anim Sci. 2006 May;84(5):1076-82. doi: 10.2527/2006.8451076x.
This study compared the adipogenic potential of porcine stromal-vascular (S-V) cells from semitendinosus muscles and s.c. adipose tissue using thiazolidinediones. Stromal-vascular cells were obtained from s.c. adipose tissue and both semitendinosus muscles from 5- to 7-d-old pigs after collagenase digestion. Preadipocyte recruitment was measured using immunohistological evaluation for AD-3, a preadipocyte antibody. Ciglitazone increased the number of preadipocytes in adipose tissue but not semitendinosus muscle S-V cell cultures, whereas 10 microM troglitazone increased preadipocyte abundance in both adipose and muscle S-V cultures by approximately 3-fold (P < 0.05). Increasing troglitazone doses did not further increase preadipocyte number. Increases in preadipocytes were paralleled by increases in CCAAT/enhancer-binding protein alpha (C/EBPalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma) positive cells in adipose tissue S-V cultures, whereas PPARgamma-reactive but not C/EBPalpha-reactive cells were increased in muscle S-V cultures treated with 10 microM troglitazone. Additionally, troglitazone treatment did not increase lipid content in s.c. adipose tissue or muscle S-V cell cultures. Cells plated on laminin-precoated culture dishes were used to determine whether troglitazone influenced adipogenesis or myogenesis in cocultures from muscle S-V cells. There was no effect on the number of myotubes or the average number of nuclei per myotube, suggesting myogenesis was not impaired by troglitazone treatment. These results suggest that regulation of intramuscular adipogenesis differs from that of subcutaneous adipogenesis.
本研究使用噻唑烷二酮类药物比较了来自半腱肌和皮下脂肪组织的猪基质血管(S-V)细胞的成脂潜能。通过胶原酶消化从5至7日龄仔猪的皮下脂肪组织和双侧半腱肌中获取基质血管细胞。使用前脂肪细胞抗体AD-3的免疫组织学评估来测量前脂肪细胞募集情况。吡格列酮增加了脂肪组织中前脂肪细胞的数量,但对半腱肌S-V细胞培养物无此作用,而10微摩尔曲格列酮使脂肪和肌肉S-V培养物中的前脂肪细胞丰度增加了约3倍(P<0.05)。增加曲格列酮剂量并未进一步增加前脂肪细胞数量。脂肪组织S-V培养物中前脂肪细胞的增加与CCAAT/增强子结合蛋白α(C/EBPα)和过氧化物酶体增殖物激活受体γ(PPARγ)阳性细胞的增加平行,而在用10微摩尔曲格列酮处理的肌肉S-V培养物中,PPARγ反应性细胞增加,C/EBPα反应性细胞未增加。此外,曲格列酮处理未增加皮下脂肪组织或肌肉S-V细胞培养物中的脂质含量。接种在层粘连蛋白预包被培养皿上的细胞用于确定曲格列酮是否影响肌肉S-V细胞共培养中的脂肪生成或肌生成。对肌管数量或每个肌管的平均核数没有影响,表明曲格列酮处理未损害肌生成。这些结果表明,肌肉内脂肪生成的调节与皮下脂肪生成的调节不同。